Successful administration of cetuximab using dose escalation method: a case report

Area of Science:

• Oncology
• Pharmacology

Background:

• Cetuximab is a critical therapy for head and neck squamous cell carcinoma and metastatic colorectal cancer.
• Severe infusion reactions are a known adverse effect of cetuximab treatment.

Observation:

• An 87-year-old East Asian female with stage IV ileocecal signet ring cell carcinoma experienced severe allergic reactions to cetuximab.
• Standard pre-treatment protocols were insufficient to prevent these reactions.

Findings:

• A modified dose escalation protocol, involving weekly incremental doses, was implemented.
• This approach, combined with comprehensive pre-treatment and vigilant monitoring, successfully mitigated allergic reactions.
• The patient safely received cetuximab therapy using this modified regimen.

Implications:

• This dose escalation strategy offers a potential alternative for patients with cetuximab hypersensitivity.
• Further research is needed to optimize personalized treatment approaches for managing cetuximab-induced hypersensitivity.
• This method may improve therapeutic options for patients with specific cancer types who are otherwise intolerant to cetuximab.